How I treat cytomegalovirus in hematopoietic cell transplant recipients

Blood

Volumn 113, Issue 23, 2009, Pages 5711-5719

  Boeckh, Michael ^a   Ljungman, Per ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; PLACEBO; PREDNISONE; RAPAMYCIN; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BLOOD DONOR; BONE MARROW TOXICITY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; ELECTROLYTE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; PATIENT MONITORING; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN; WILD TYPE; ANIMAL; BLOOD; DRUG EFFECT;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RISK FACTORS;

EID: 67651085554     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-143560     Document Type: Review

References (109)

1. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407-414. (Pubitemid 36077556)
2. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111-1116. (Pubitemid 27267735)
3. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997;176:782-785.
4. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240-2245.
5. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112:228-236. (Pubitemid 32151176)
6. Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis. 2002;35:703-712. (Pubitemid 35024731)
7. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273-282. (Pubitemid 34107239)
8. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986;67:1162-1167. (Pubitemid 16116435)
9. Martino R, Rovira M, Carreras E, et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica. 2001;86:1075-1086. (Pubitemid 33031874)
10. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78-83. (Pubitemid 43235389)
11. Söderberg C, Larsson S, Bergstedt-Lindqvist S, Möller E. Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol. 1993;67:3166-3175.
12. Söderberg C, Larsson S, Rozell BL, Sumitran KS, Ljungman P, Möller E. Cytomegalovirus-induced CD13-specific autoimmunity-a possible cause of chronic graft-vs-host disease. Transplantation. 1996;61:600-609. (Pubitemid 26073606)
13. Larsson K, Aschan J, Remberger M, Ringden O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation. 2004;77:526-531. (Pubitemid 38282806)
14. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373-1380.
15. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060-3067. (Pubitemid 37248884)
16. Chen C, Busson M, Rocha V, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006;38:437-444. (Pubitemid 44340375)
17. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006;107:1230-1232. (Pubitemid 43156330)
18. Albano MS, Taylor P, Pass RF, et al. Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening. Blood. 2006;108:4275-4282. (Pubitemid 44913304)
19. Tomonari A, Takahashi S, Ooi J, et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol. 2008;80:251-257. (Pubitemid 351253457)
20. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-1010. (Pubitemid 16138695)
21. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195-4200. (Pubitemid 36857904)
22. Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis. 2002;34:347-350. (Pubitemid 34746253)
23. Bowden R, Cays M, Schoch G, et al. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood. 1995;86:3598-3603.
24. Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 2001;15:1-20. (Pubitemid 32057942)
25. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41:1310-1319.
26. Trenschel R, Ross S, Husing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 2000;25:665-672. (Pubitemid 30156593)
27. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant [see comments]. J Infect Dis. 1991;164:483-487.
28. Ruutu T, Ljungman P, Brinch L, et al. No prevention of cytomegalovirus infection by anticytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant. 1997;19:233-236.
29. Boeckh M, Bowden R, Storer B, et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:343-351. (Pubitemid 32677436)
30. Ljungman P, De La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050-3056. (Pubitemid 34525398)
31. Ljungman P, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status influences the outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation; an EBMT megafile analysis. Blood. 2003;102:4255-4260. (Pubitemid 37494081)
32. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant. 2004;10:128-134.
33. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043-2051.
34. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003-2008. (Pubitemid 38326213)
35. Ozdemir E, Saliba R, Champlin R, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40:125-136. (Pubitemid 47046210)
36. Patel S, Ridwan R, Ortin M. Cytomegalovirus reactivation in pediatric hematopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol. 2005;27:411-415. (Pubitemid 41233295)
37. Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12-18. (Pubitemid 17015185)
38. Zikos P, Van Lint MT, Lamparelli T, et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica. 1998;83:132-137.
39. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in patients undergoing haematopoietic stem cell transplantation: systematic review and meta-analysis [abstract]. Bone Marrow Transplant. 2008;41:S46. Abstract O267.
40. Bass E, Powe N, Goodman S, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1993;12:179-183. (Pubitemid 23268164)
41. Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta analysis. Bone Marrow Transplant. 1994;13:163-168. (Pubitemid 24059140)
42. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705-712. (Pubitemid 20288939)
43. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem cell transplantation? A randomized, double-blind, dose effect, placebo-controlled multicenter trial. Ann Intern Med. 2003;139:8-18. (Pubitemid 38124614)
44. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70-75. (Pubitemid 18029297)
45. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749-753.
46. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749-758.
47. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178. (Pubitemid 23034801)
48. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-184.
49. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071. (Pubitemid 26383133)
50. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes. 2008;15:4-12.
51. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-2508. (Pubitemid 27392736)
52. Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune- suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant. 1995;16:401-405.
53. Atkinson K, Downs K, Golenia M, Biggs J, et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol. 1991;79:57-62.
54. Przepiorka D, Ippoliti C, Panina A, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994;13:461-464. (Pubitemid 24116749)
55. von Bueltzingsloewen A, Bordigoni P, Witz F, et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:197-202. (Pubitemid 23268152)
56. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients [see comments]. J Infect Dis. 1992;166:473-479.
57. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant. 1994;13:783-788. (Pubitemid 24195796)
58. Bregante S, Bertilson S, Tedone E, et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant. 2000;26:23-29. (Pubitemid 30456106)
59. Winston D, Young J, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403-5410.
60. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355:2032-2036. (Pubitemid 30339241)
61. Stachel D, Kirby K, Corey L, Boeckh M. CMV viral load as predictor for transplant-related mortality in the era of pre-emptive therapy. Bone Marrow Transplant. 2008;41:S46.
62. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev. 1998;11:533-554. (Pubitemid 28379099)
63. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 2004;42:1142-1148. (Pubitemid 38332838)
64. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant. 2004;10:433-447.
65. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007;40:865-869. (Pubitemid 350020321)
66. Fries BC, Riddell SR, Kim HW, et al. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant. 2005;11:136-148. (Pubitemid 40186211)
67. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623. (Pubitemid 46732528)
68. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008;111:1816-1819.
69. Boeckh M, Nichols W, Chemaly R, et al. Prevention of late CMV disease after HCT: a randomized double-blind multicenter trial of valganciclovir prophylaxis versus PCR-guided GCV/VGCV preemptive therapy [abstract]. Biol Blood Marrow Transplant. 2008;14:30. Abstract 75.
70. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol. 1993;83:118-124. (Pubitemid 23030182)
71. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922. (Pubitemid 35332029)
72. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
73. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLAtetramers. Blood. 2001;98:505-512.
74. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis. 2007;196:699-704. (Pubitemid 47293851)
75. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-763. (Pubitemid 30189517)
76. Limaye AP, Huang ML, Leisenring W, Stensland L, Corey L, Boeckh M. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stemcell transplant recipients. J Infect Dis. 2001;183:377-382. (Pubitemid 32105596)
77. Hebart H, Ljungman P, Klingebiel T, et al. Prospective comparison of PCR-based versus late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allogeneic stem cell transplantation [abstract]. Blood. 2003;102:195a.
78. Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood. 2003;101:5053-5060. (Pubitemid 36857773)
79. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18:233-246. (Pubitemid 352018847)
80. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867-874. (Pubitemid 32154267)
81. Manion DJ, Vibhagool A, Chou TC, Kaplan J, Caliendo A, Hirsch MS. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antivir Ther. 1996;1:237-245. (Pubitemid 126690066)
82. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A. 2000;97:8039-8044.
83. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124-127. (Pubitemid 44441975)
84. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother. 2006;50:3470-3472. (Pubitemid 44527529)
85. Efferth T, Romero M, Wolf D, Stamminger T, Marin J, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47:804-811.
86. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 2004;34:1071-1075. (Pubitemid 40028840)
87. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis. 2007;9:28-32. (Pubitemid 46257196)
88. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc Natl Acad Sci U S A. 2006;103:14182-14187. (Pubitemid 44453000)
89. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110:490-500.
90. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis. 2008;10:13-18. (Pubitemid 351171315)
91. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214-219. (Pubitemid 32524790)
92. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543-558. (Pubitemid 38351787)
93. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097. (Pubitemid 34289682)
94. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005-1011.
95. Cathomas G, Morris P, Pekle K, Cunningham I, Emanuel D. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood. 1993;81:1909-1914. (Pubitemid 23101608)
96. Hackman RC, Wolford JL, Gleaves CA, et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. Transplantation. 1994;57:231-237.
97. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159-1164. (Pubitemid 34547067)
98. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107:3002-3008.
99. Winston DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant. 2006;12:635-640.
100. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777-782. (Pubitemid 19046044)
101. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783-788. (Pubitemid 19046045)
102. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation. 1988;46:905-907. (Pubitemid 19013240)
103. Ljungman P, Cordonnier C, Einsele H, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 1998;21:473-476. (Pubitemid 28107954)
104. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
105. Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26:413-417.
106. Erard V, Guthrie K, Smith J, Chien J, Corey L, Boeckh M. Cytomegalovirus pneumonia after hematopoietic cell transplantation: outcomes and factors associated with mortality. Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 2007. Abstract V-1379.
107. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpes-viruses in vitro. Antimicrob Agents Chemother. 2005;49:3724-3733. (Pubitemid 41233024)
108. Schleiss MR, Bernstein DI, McVoy MA, et al. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 2005;65:35-43.
109. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413-422. (Pubitemid 352040253)